Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16579394 | 1.00 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL16579360 | 1.00 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL2356808 | 1.00 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL7919683 | 1.00 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL22679988 | 0.89 | MAPT (0.44) | MAPTPKMMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL22491857 | 0.88 | MAPT (0.47) | MAPTPKMSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9087268 | 0.83 | MEN1 (0.46) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL19048799 | 0.83 | MAPT (0.40) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL68965 | 0.83 | MEN1 (0.46) | MAPTPKMMEN1BLMKMT2A | |
| SCHEMBL29277719 | 0.81 | MEN1 (0.37) | MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350061-B1 | 2,3-DISUBSTITUTED PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8357700-B2 | 2,3-disubstituted piperidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357700-B2 | 2,3-disubstituted piperidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20110263643-A1 | 2,3-Disubstituted Piperidine Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-10-27 | — | — | US | disclosed |
| US-20110263643-A1 | 2,3-Disubstituted Piperidine Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-10-27 | — | — | US | disclosed |
| WO-2010048016-A1 | 2,3-DISUBSTITUTED PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263643-A1 | 2,3-Disubstituted Piperidine Orexin Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | MAPT 960/4885PKM 3692/4885MEN1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.